title: Estrogen therapy for postmenopausal osteoporosis.
abstract: Osteoporosis is a worldwide problem that results in fractures that lead to disability and high costs to society. Estrogen therapy is frequently utilized for postmenopausal symptoms, but also has proven protective effects on the skeleton. The main action of estrogen at the cellular level is to inhibit the osteoclast by increasing levels of osteoprotegerin (OPG). OPG binds to the receptor activator of NFkB and prevents osteoclast differentiation, activity and survival. Numerous trials have demonstrated the positive effect estrogen has on the improvement of bone mineral density, and lower doses have also proven efficacious with fewer side effects. Both observational and randomized clinical trials have demonstrated the ability of estrogen treatment to prevent fractures. Topics that remain controversial include the appropriate length of estrogen treatment for postmenopausal women and the appropriate follow-up after treatment discontinuation.
authors.affiliation: Amgen, Inc., Thousand Oaks, CA 91361, USA. lfitzpat@amgen.com
authors.forename: Lorraine A
authors.initials: LA
authors.lastname: Fitzpatrick
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016387:Women's Health